KRAS Testing for Colorectal Cancers (CRC)

By: | Tags: | Comments: 0 | August 13th, 2016

  • Colorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States and nearly 50% of patients will experience metastases during their lives.
  • Anti EGFR targeted therapy is used for treatment of metastatic colorectal cancer.
  • Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene.
  • This mutated KRAS gene is predictive of resistance to EGFR therapies in advanced colorectal cancer.
  • NCCN guidelines on colon cancer (Feb.2016) recommend that all patients with metastatic colorectal cancer should have tumor tissue genotyped for KRAS mutations.

Result reported: Positive or Negative for KRAS mutations

Lincoln Labs KRAS Mutation Analysis offers:

  • Turnaround time of 7-10 days
  • Our highly qualified staff is accessible for any assistance regarding the tests.
  • Broad coverage by most private and public insurance.

Specimen Requirement:

  1. Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and standard for KRAS mutation analysis.
  2. Specimens are optimally fixed in 10% neutral-buffered formalin, optimal fixation time ranges from 6 to 24 hours.
  3. Presence of tumor cells in the sample must be assessed by a pathologist.
  4. Ratio of tumor cells to normal cells is crucial for adequate mutation testing and should be provide by the pathologist.
  5. One H&E slide and 3-5 unstained slides (6-8microns ideal) are required for mutation testing.

Test Code:

ICD 10 Code:81275- KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis, variants in exon 2 (eg, codons 12 and 13)

Leave a Reply

11 − two =